Immuneering

Yahoo Finance • 5 days ago

Immuneering Prepares To Share 12-Month Survival Data In Pancreatic Cancer Trial

(RTTNews) - Immuneering Corporation (IMRX) announced that it will present updated 12-month overall survival data from its ongoing Phase 2a trial of Atebimetinib in combination with modified gemcitabine / nab-paclitaxel (mGnP) in first-line... Full story

Yahoo Finance • 11 days ago

Immuneering To Initiate Phase 3 Atebimetinib Trial In Pancreatic Cancer In Mid-2026

(RTTNews) - Immuneering Corp. (IMRX), a late-stage clinical oncology company, announced that it is on track to dose the first patient in its planned phase 3 trial of Atebimetinib in first-line metastatic pancreatic cancer patients in mid-2... Full story

Yahoo Finance • 13 days ago

Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)

Immuneering Corporation NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it i... Full story

Yahoo Finance • last month

Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

PALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and platform immunotherapies reshape treatment... Full story

Yahoo Finance • 2 months ago

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

- Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP - - Raised $225 million of financing, including $25 million private placement with Sanofi - - Cash runwa... Full story

Yahoo Finance • 3 months ago

SA Asks: What's the most attractive biotech stock right now?

[Genetic research and Biotech science Concept. Human Biology and pharmaceutical technology] jittawit.21 What's the most attractive biotech stock right now for investors? Seeking Alpha analysts ONeil Trader [https://seekingalpha.com/autho... Full story

Yahoo Finance • 3 months ago

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30... Full story

Yahoo Finance • 3 months ago

Biggest stock movers Thursday: INTC, RIG, and more

[Emerging Financial Data - Stock Market, Prosperity, Bull Market - Blue Version] DKosig Stock futures ticked higher in the premarket hours of Thursday as investors awaited the release of key jobs data, hoping for signals on labor market s... Full story

Yahoo Finance • 3 months ago

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the pricing of its underwritten public offering of 18,959,91... Full story

Yahoo Finance • 3 months ago

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a proposed underwritten public offering of shares of its Cla... Full story

Yahoo Finance • 3 months ago

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

- 86% overall survival (OS) observed at 9 months; standard of care benchmark is ~47% - - 53% progression-free survival (PFS) observed at 9 months; standard of care benchmark is ~29% - - Company expects regulatory feedback on pivotal tria... Full story

Yahoo Finance • 4 months ago

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

- Company plans to host an investor call at 8 a.m. ET on September 25 - - Immuneering plans to then share the updated data at the PanCAN Scientific Summit on September 28 - - Additionally, the Company will present a review of preclinical... Full story

Yahoo Finance • 4 months ago

Eli Lilly (LLY) Reports Positive Outcomes for Verzenio in Breast Cancer Trial

Eli Lilly announced positive results from the Phase 3 MonarchE trial, demonstrating Verzenio's effectiveness in treating early breast cancer, which has reinforced confidence in the company's oncology portfolio. Meanwhile, the Phase 3 ATTAI... Full story

Yahoo Finance • 4 months ago

Immuneering closes $25 million private placement to accredited investors

CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), whose stock has surged over 170% year-to-date according to InvestingPro data, announced Tuesday it has closed its previously announced private placement, raising approximately $25 m... Full story

Yahoo Finance • 4 months ago

Immuneering Announces Closing of $25 Million Private Placement

CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the closing of its previously announced private place... Full story

Yahoo Finance • 4 months ago

TD Cowen reiterates Buy rating on Eli Lilly stock after Phase III data

Investing.com - TD Cowen has reiterated a Buy rating and $960.00 price target on Eli Lilly (NYSE:LLY), a prominent player in the pharmaceuticals industry with a market cap of $652 billion, following the company’s release of Phase III trial... Full story

Yahoo Finance • 4 months ago

Immuneering stock soars on clinical supply deal with Eli Lilly

Investing.com -- Immuneering Corp (NASDAQ:IMRX) stock surged 21.7% Monday after the clinical-stage oncology company announced a clinical supply agreement with Eli Lilly and Company (NYSE:LLY) for its second-generation KRAS G12C inhibitor,... Full story

Yahoo Finance • 4 months ago

Immuneering signs supply deal with Lilly to test atebimetinib plus olomorasib

[Scientist, doctor or technician doing a drug trial, test or experiment while working in a lab, science facility or hospital. One medical researcher, expert or professsional making a discovery at work] Sean Anthony Eddy Immuneering (NASDA... Full story

Yahoo Finance • 4 months ago

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

Immuneering Corporation - Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering... Full story

Yahoo Finance • 4 months ago

Top stock movements in today's session.

Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMEN... Full story